Structural basis of interaction between the hepatitis C virus p7 channel and its blocker hexamethylene amiloride  

作　　者：Linlin Zhao Shuqing Wang Lingyu Du Jyoti Dev Liujuan Zhou Zhijun Liu James J. Chou Bo OuYang 

机构地区：[1]National Center for Protein Science, State Key Laboratory of Molecular Biology, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai 200031, China [2]Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin 300070, China [3]Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA [4]Shanghai Science Research Center, Chinese Academy of Sciences. Shanahai 201204. China

出　　处：《Protein & Cell》2016年第4期300-304,共5页蛋白质与细胞（英文版）

摘　　要：Dear Editor, Hepatitis C virus （HCV） infection, which causes hepatitis C and can chronically lead to serious and life-threatening dis- eases including liver cirrhosis and hepatocellular carcinoma （Lauer and Walker, 2001）, is a rising global health problem. More than 170 million people are infected by HCV worldwide and 3-4 million people are infected each year. No effective vaccines are available to prevent HCV infection. Moreover, HCV is a fast mutating RNA virus with seven distinct genotypes and many subtypes within each genotype. The high degree of genetic diversity can lead to further viral resistance to the current therapies within individual patients （Li et al., 2012）. Hence, there remains a strong desire in the medical community to explore new therapeutic opportunities.Dear Editor, Hepatitis C virus （HCV） infection, which causes hepatitis C and can chronically lead to serious and life-threatening dis- eases including liver cirrhosis and hepatocellular carcinoma （Lauer and Walker, 2001）, is a rising global health problem. More than 170 million people are infected by HCV worldwide and 3-4 million people are infected each year. No effective vaccines are available to prevent HCV infection. Moreover, HCV is a fast mutating RNA virus with seven distinct genotypes and many subtypes within each genotype. The high degree of genetic diversity can lead to further viral resistance to the current therapies within individual patients （Li et al., 2012）. Hence, there remains a strong desire in the medical community to explore new therapeutic opportunities.

分 类 号：Q78[生物学—分子生物学] TU391[建筑科学—结构工程]